OJSC RUSNANO withdrew from Nearmedic Pharma LLC, RUSNANO informed.
Prior to its withdrawal, RUSNANO owned a ca. 34.45% equity stake in Nearmedic Pharma.
It will be recalled that Russia's Federal Antimonopoly Service granted RUSNANO's application for the purchase of a 34.45% equity stake in Nearmedic Pharma LLC (Obninsk, Kaluga region) aimed at increasing its interest in the target company to 97.27%.
In October 2011, RUSNANO and Nearmedic Plus LLC were reported to have agreed to set up a universal GMP enterprise to implement a full sequence of operational procedures for the production of original nano-products related to the sphere of polymeric pharmaceuticals currently undergoing rapid development worldwide. The project budget was projected at more than RUB 4 billion including co-funding in the amount of RUB 1.2 billion to be provided by RUSNANO. The new plant was expected to be launched in Obninsk (Kaluga region) in late 2013.
The new enterprise was expected to primarily focus on the production of Kagocel, an OTC viricide currently produced at leased premises.
The mission of RUSNANO (tax number: 7728131587) established in March 2011 through reorganization of state corporation Russian Corporation of Nanotechnologies, is to pursue the state policy in the sphere of nanotechnologies co-investing in nano-technological projects with a promising economic or social outlook. The company's priorities are: optoelectronics, nanoelectronics, mechanical engineering, metal working, solar power, healthcare, biotechnologies, energy-efficient solutions and nanostructured materials.
The company's authorized capital is RUB 53.741 billion represented by 53,741,700,000 common shares at par value of 1 ruble. The Russian Federation holds 100% of RUSNANO shares.
IFRS net loss of the company for 2012 was RUB 21.813 billion against a net profit of RUB 1.007 billion in 2011. Revenue went up 2.8 times to RUB 6.942 billion from RUB 2.498 billion.
According to the information and retrieval system DataCapital, RAS net loss of RUSNANO for January-September 2013 grew 2.1-fold to RUB 2.302 billion from RUB 1.091 billion for the same period in 2012. Revenue increased by 25.8% to RUB 6.014 billion from RUB 4.781 billion, sales profit 3.4-fold to RUB 1.258 billion from RUB 371.710 million, loss before tax 2.2-fold to RUB 2.835 billion from RUB 1.29 billion.